Key insights
- Merck's stock (MRK) may see a positive impact following the FDA's Breakthrough Therapy designation for its investigational drug calderasib, in combination with Keytruda, for advanced non-small cell lung cancer. This designation accelerates development and review, reflecting strong investor confidence in Merck's oncology pipeline and its financial health. The news highlights potential for future revenue growth and innovation within the biotechnology sector, which could translate to broader market optimism for healthcare stocks.
RAHWAY, N.J. - Merck (NYSE:MRK) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to calderasib (MK-1084) in combination with Keytruda for the first-line treatment of patients with advanced or metastatic non-small cell lung cancer with KRAS G12C-mutation and expressing PD-L1 with a tumor proportion score of at least 1%, according to a press release statement. The pharmaceutical giant, with a market capitalization of $296 billion, has seen its stock surge 63% over the past year, reflecting investor confidence in its oncology pipeline.
This marks the first Breakthrough Therapy designation for calderasib, an investigational oral KRAS G12C inhibitor. The designation was supported by positive data from the Phase 1 KANDLELIT-001 trial.
The KRAS G12C mutation occurs in approximately 14% of patients with non-small cell lung cancer adenocarcinoma, making it the most frequently observed KRAS mutation in patients. Merck’s strong financial position supports its extensive R&D efforts, with the company generating $65.77 billion in revenue and maintaining an impressive 77% gross profit margin. According to InvestingPro analysis, the stock currently appears undervalued relative to its Fair Value, presenting a potential opportunity for investors. The platform reveals 14 additional ProTips for MRK subscribers.
The FDA’s Breakthrough Therapy designation is granted to expedite development and review of medicines intended to treat serious or life-threatening conditions when preliminary clinical evidence indicates the product may demonstrate substantial improvement over available therapies. Benefits include more intensive FDA guidance, organizational commitment involving senior managers, rolling review and potential eligibility for Priority Review.
Merck is developing calderasib through a collaboration with Taiho Pharmaceutical Co. Ltd. and Astex Pharmaceuticals (UK), a subsidiary of Otsuka Pharmaceutical Co., Ltd., announced in January 2020.
The KANDLELIT clinical development program includes five Phase 3 trials evaluating calderasib across various tumor types and stages, including combinations with Keytruda and Keytruda QLEX for different non-small cell lung cancer patient populations, and trials in colorectal cancer.
Mutations in KRAS are among the most prevalent mutations found in cancer, occurring with high frequency in non-small cell lung cancer, pancreatic, urogenital and colorectal cancers. For deeper insights into Merck’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available for MRK and 1,400+ other US equities on InvestingPro.
In other recent news, Merck has announced several key developments. The company declared a quarterly dividend of $0.85 per share for the third quarter of 2026, payable on July 8, 2026, to shareholders of record as of June 15, 2026. Additionally, Merck is raising $6 billion through a bond sale to refinance debt from its acquisition of Terns Pharmaceuticals Inc. Furthermore, the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Merck’s Keytruda in combination with Padcev for certain bladder cancer patients, with a decision expected by the third quarter of 2026. Merck’s Phase 3 TroFuse-005 trial for its endometrial cancer drug, sacituzumab tirumotecan, met its primary endpoints, showing significant improvements in overall survival and progression-free survival. The company also participated in a roundtable hosted by China’s commerce ministry with over 50 foreign pharmaceutical firms, highlighting its involvement in international discussions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.